Biotechnology
Synthetic Biology for Tennessee Schools: BioBuilder Partners with Niswonger Foundation on $8.8M Federal Grant for STEM Education
CAMBRIDGE, Mass. — The BioBuilder Educational Foundation announced that they are to partner with the Niswonger Foundation on their award of an “Education Innovation and Research” (EIR) Grant from the U.S. Department of Education that will focus on educational opportunities in Science, Technology, Engineering and Mathematics (STEM)….
Pure Protein, LLC Announces New Website Now Offering Its HLA Reagents and Technical Services to Researchers
OKLAHOMA CITY, Okla. — Pure Protein, LLC (Pure Protein) an HLA company that has developed comprehensive analytical capabilities in the field of human leukocyte antigen (HLA) immunology and an approach to produce soluble forms of the HLA molecule (sHLA), is proud to announce the launch of its new website….
Zeteo Biomedical to Collaborate with Iowa State University Nanovaccine Institute to Study a COVID 19 Vaccine Under Fast Track CARES Act Funded Program
AUSTIN, Texas — Zeteo Biomedical LLC, Inc., a privately held medical device company, has partnered with the Nanovaccine Institute at Iowa State University to study a nasal SARS-CoV-2 vaccine. Zeteo will provide nasal delivery device technology and unit dose packaging utilizing its ZEOx2 Delivery Platform….
Avila Herbals Announces Manufacturing and Research and Development Agreements with Phoenix Biotechnology
CHRISTIANSBURG, Va. — Avila Herbals, a company specializing in novel botanical extraction techniques for both dietary supplements and pharmaceuticals, announced today that it has signed an exclusive global manufacturing agreement and a research and development agreement with Phoenix Biotechnology….
Progenabiome Shares New Data on Fecal Transplant, Sars-Cov-2 at ACG 2020
VENTURA, Calif. — The American College of Gastroenterology (ACG) named Progenabiome “Outstanding Poster Presenter” for its poster: “Successful Bacterial Engraftment Identified by Next Generation Sequencing Following Fecal Microbiota Transplantation for Clostridioides difficile Infection,” which will be presented virtually at the ACG Annual Scientific Meeting this week….
Pure Protein, LLC to Exhibit and Preview New Website at the American Society for Histocompatibility and Immunogenetics (ASHI) 46th Annual Meeting
OKLAHOMA CITY, Okla. — Pure Protein, LLC (Pure Protein) an HLA company that has developed comprehensive analytical capabilities in the field of human leukocyte antigen (HLA) immunology and an approach to produce soluble forms of the HLA molecule (sHLA), announced today that it will be an exhibitor at the ASHI VIRTUAL ANNUAL MEETING, October 19 – 21, 2020….
Zeblok Computational Announces Partnership with Laufer Center and CEWIT – COVID-19 Drug Discovery
STONY BROOK, N.Y. — Zeblok Computational is contributing to the efforts of two groups of researchers at The Laufer Center for Physical and Quantitative Biology, for COVID-19 drug discovery by providing Zeblok’s secure, scalable Supercomputing-as-a-Service platform, employing 128 GPUs from the CEWIT SMART GPU Cluster….
ROKiT Pharma’s Preclinical Studies Showing Tremendous Promise for Naturally Derived Cancer Drug, ROK-001 – Moving Towards The Initiation Of Phase 1b/2 Clinical Trial
LOS ANGELES, Calif. — ROKiT Pharma, Inc., a public-benefit corporation dedicated to putting patients first, announced today it is rapidly progressing through final preclinical studies and moving forward with preparation for the initiation of a Phase 1b/2 clinical trial of ROK-001, a potentially low toxicity cancer drug derived from natural ingredients….
Lyme Disease Biobank Expands Into San Diego
SAN DIEGO, Calif. — Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the U.S., announces the opening of the San Diego collection site of the Bay Area Lyme Foundation’s Lyme Disease Biobank, which is the first program to provide researchers with blood and urine samples from people with early Lyme disease from multiple endemic regions across the country….
iCell Gene Therapeutics Announces CAR-T Oral and Poster Presentations at 61st American Society of Hematology Annual Meeting
STONY BROOK, N.Y. — iCell Gene Therapeutics, a clinical stage biopharmaceutical company focused on immunotherapies for hematologic malignancies, solid tumors, organ rejections and autoimmune disorders, announced today that it will give oral and poster presentations related to its BCMA-CD19 cCAR and CD4-specific CAR programs at the 61st American Society of Hematology (ASH) Annual Meeting to be held December 7-10, 2019 in Orlando, Florida….